BioSpace News Archive

XHANCE is the first and only nasal medication ever shown in Phase 3 controlled trials to reduce exacerbations for patients with chronic sinusitis.

XORTX Therapeutics Inc. is pleased to announce positive topline results from Part 1 of the three part Pharmacokinetics Bridging Study – XRX-OXY-101 (“PK Clinical Trial”) - showing a substantial increase in oral bioavailability of two versions of XORTX’s proprietary oxypurinol formulation compared to a control formulation.

On July 11, 2022, VenusP-ValveTM, Venus Medtech’s in-house developed innovative transcatheter pulmonic valve replacement system, was approved by China’s National Medical Products Administration for the treatment of severe pulmonary regurgitation in patients after congenital heart defects procedure with native right ventricular outflow tract.

Synchron , an endovascular brain-computer (BCI) interface company, today announced the appointment of Kurt Haggstrom as Chief Commercial Officer. Haggstrom brings an extensive background in medical device commercialization and product launches, with a technical background in R&D engineering, holding over 20 U.S. patents.

Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical study evaluating BAT8006, an antibody drug conjugate (ADC) that targets folic acid receptor α (FRα).

Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Brian Wong as a member of its Board of Directors.

Collaboration integrates DNAnexus’ proven biomedical data analysis platform with Twist’s NGS Methylation Detection and Unique Molecular Identifier Adapter Systems.

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“ FSD Pharma ” or the “ Company ”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that is wholly owned subsidiary, Lucid Psycheceuticals Inc. (“ Lucid ”), filed a provisional patent application on novel formulations of palmitoylethanolamide (PEA).

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, including drug resistant depression, is named Top Non-Invasive Devices Provider in 2022 by MedTech Outlook magazine for its NeuroStar Advanced Therapy for Mental Health.

BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Brady Granier, President and Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc., will be participating in the Benzinga All Access event taking place on July 15, 2022.